Compare BioNano Genomics Inc (BNGO) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs SkyWest Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while SkyWest Inc trades at $107.89 (market cap $4.19B). The key difference: SkyWest Inc is far larger — about 306.7× BioNano Genomics Inc's market cap, and SkyWest Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SKYW | |
|---|---|---|
Market Cap | $13.66M | $4.19B |
Sector | Health | Technology |
52-Week High | $4.92 | $123.72 |
52-Week Low | $1.06 | $78.40 |
Enterprise Value | $16.26M | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
SkyWest (SKYW) trades at $107.23, down 0.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and net income margin of 9.78%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales amid company buybacks, while analyst consensus remains positive with a $109.33 price target. Cash flow improved in 2026 to a net positive $33 million from a $105 million deficit in 2025.
The outlook for SKYW is cautiously optimistic, supported by undervalued metrics and bullish analyst ratings, but risks include earnings volatility and insider selling. Investment opportunity lies in its low valuation and operational cash flow growth, though investors should monitor fuel cost pressures and competitive dynamics in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
